Table 2 On-going clinical trials targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1) antigen

Anti-NY-ESO-1 TCR

Cyclophosphamide

Synovial sarcoma, melanoma, esophageal cancer, ovarian cancer, lung cancer, bladder cancer, liver cancer

1

NCT02869217

Cyclophosphamide + transforming growth factor-beta receptor II (TGFbDNRII)-transduced autologous tumor infiltrating lymphocytes

Adult solid neoplasm

1 and 2

NCT02650986

Cyclophosphamide

Bone Sarcoma, soft tissue sarcoma, melanoma, liver cancer, esophageal cancer, breast cancer, thyroid cancer, ovarian cancer

1

NCT03159585

None

Advanced malignant solid tumors

1

NCT03047811

Cyclophosphamide, fludarabine

Bladder carcinoma, breast cancer, esophagus carcinoma, lung cancer, melanoma, multiple myeloma, neuroblastoma, ovarian cancer, synovial sarcoma, other metastatic solid cancers

1

NCT02457650

Aldesleukin, cyclophosphamide, decitabine

Recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma

1

NCT03017131

Cyclophosphamide

Lung cancer, non-small cell lung cancer

NCT03029273

Pembrolizumab

Multiple myeloma

1

NCT03168438

NY-ESO-1 TCR +

NY-ESO-1 peptide Vaccine

Aldesleukin, cyclophosphamide, fludarabine phosphate, nivolumab

Neoplasms

1

NCT02775292

NY-ESO-1 TCR+

NY-ESO-1 protein vaccine

Cyclophosphamide, fludarabine phosphate, aldesleukin, radiation

Solid tumors

1

NCT02366546

NY-ESO-1 protein vaccine

Atezolizumab, guadecitabine, carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-l-lysine (Poly ICLC)

Recurrent fallopian tube carcinoma

Recurrent ovarian carcinoma

Recurrent primary peritoneal carcinoma

1 and 2

NCT03206047

NY-ESO-1 peptide vaccine

Montanide ISA-51, polyinosinic-polycytidylic acid, and poly-l-lysine (Poly ICLC), Cyclophosphamide, Fludarabine, Interleukin-2

Melanoma

2

NCT02334735